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Monocyte cell-surface CD14 expression and soluble CD14 antigen in
hemodialysis: Evidence for chronic exposure to LPS. Expression of CDI4
on peripheral blood monocytes and serum levels of the 53 kD soluble
CD14 antigen were investigated in patients with end-stage renal failure
who were undergoing chronic hemodialysis (HD) with either cuprophane/
hemophane (CU/HE) low-flux (LF) or polysulfone/polyamide (PS/PA)
high-flux (HF) membranes. Baseline expression of CD14 was significantly
lower in HD patients compared to uremic patients and normal controls.
Patients using PS/PA membranes disclosed a further decreased CD14
expression than patients with CU/HE membranes. Specific fluorescence
intensity for CD14 increased 15 minutes after the start of the dialysis
session and was on average 22% higher after hemodialysis. The serum
levels of sCD14 were elevated about 2.5-fold in HD patients compared to
healthy controls (5.4 1.3 vs. 2.2 0.5 mg/liter, P < 0.0001) and were
significantly higher compared to non-dialyzed patients with chronic renal
failure (3.9 1.0 mg/liter, P <0.001). After regular dialysis with high-flux
membranes, soluble CD14 serum concentrations significantly increased
(P < 0.001) compared to pre-dialysis levels. Values of soluble CD8 (54
kD) were elevated only 1.5-fold in HD patients relative to healthy
controls, whereas serum levels of the low molecular weight soluble CD23
(20 kD) 12 and 19-fold in patients treated with HF-HD and LF-HD,
reflecting the renal impairment and filtration through HF membranes.
Thus, high sCD14 values in HD patients may stem from increased release
of the up-regulated membrane antigen due to monocyte activation during
hemodialysis treatment. Since the CDI4 antigen is involved in LPS-
induced monocyte activation, the influence of lipopolysaccharide on CD14
expression and sCDI4 release was investigated in vitro. Addition of 1
ng/ml or 0.01 ng/ml LPS to whole blood significantly enhanced monocyte
CD14 expression after 30 or 60 minutes of incubation. The release of
soluble CD14 by cultured peripheral blood monocytes significantly in-
creased in the presense of 0.01 ng/ml LPS during a five-day incubation
experiment. Our results demonstrate an enhanced expression of CD14 by
monocytes after HD and increased sCD14 serum levels possibly due to
chronic exposure to trace amounts of endotoxins, as supported by in vitro
experiments.
Patients with end-stage renal failure under long-term hemodi-
alysis exhibit an impaired immune response where disruption of
the phagocytic cell function may play a pivotal role. While some
detailed infomation concerning changes in granulocyte function
[1—4] and cell surface antigen expression [5, 6] has recently been
extensively reviewed [7], the function of monocytes/macrophages
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related to hemodialysis is not well understood. An altered mac-
rophage Fe-receptor function in vivo [8] and a reduced phagocytic
capacity in vitro [9] have been reported. However, most studies
focused on the release of monocyte-derived cytokines (IL-I, IL-6,
TNF-a) under in vitro conditions [10—14], or on the determination
of cytokine serum levels [15—18; reviewed 19]. Overall, these data
suggest that hemodialysis is associated with monocyte activation.
At present, it is still unclear if such monocyte activation occurs
primarly through contact with the membrane material or is due to
endotoxin transfer across the dialyzer membrane during hemodi-
alysis. The transmembrane passage of LPS or LPS-fragments from
the dialysate to the blood compartment is, although not un-
doubted, documented by numerous reports [20—22]. The activa-
tion of monocytes through LPS occurs via specific cell-surface
antigens that act as receptors for the lipid-A moiety of LPS [23].
One known receptor for LPS is the 55 kD glycosyl-phosphatidyl-
inositol (GPI)-anchored myeloid differentiation antigen CDI4
which is expressed on peripheral blood monocytes and macro-
phages [24, 25]. Upon entry into the bloodstream LPS is corn-
plexed to LPS-binding protein (LBP) [261, a 60 kD serum protein
with a lipid-A binding site [271. This LBP/LPS complex then
recognizes the cell surface CDI 4 antigen on monocytes/macro-
phages [25, 28, 291, leading to an enhanced cytokine production
[30, 311.
However, the exact molecular basis of the CD14-mediated
events is unknown. In this regard, a 53 kD soluble form of CD14
(sCD14) detectable in human serum [32] and monocyte culture
supernatants [33] may have immunological relevance. Recently, it
has been reported that the LPS-induced activation of cells that do
not themselves express CD14 is mediated by soluble CD14 [34,
35]. Thereby high concentrations of LPS induce an activation in
the presence of sCD14 alone, whereas at low LPS concentrations
the sCD14-stimulated activation was strongly enhanced by LPS-
binding protein [36]. This indicates that the membrane form of
CD14 behaves as a LPS receptor, and its soluble form may serve
as a co-ligand for LPS-mediated cell activation.
In the present study we investigated changes in the expression
of CD14 on peripheral blood monocytes from patients undergoing
hernodialysis who also show augmented sCD14 serum levels.
Furthermore, we assessed the influence of LPS, which apparently
plays a critical role in extracorporal blood purification, on CD14
expression and sCDI4 release under in vitro conditions.
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Methods
Patient characteristics
Twenty-five patients on chronic maintenance hemodialysis
(HD) were selected for study after informed consent was ob-
tained. The mean age was 51.6 (range 27 to 73) with a mean time
of hemodialysis treatment of seven years (range 2 to 14) prior to
the study. All patients had stable disease and underwent four to
five hours of maintenance hemodialysis thrice weekly. Except for
medication including phosphate binders, multivitamins, ACE-
inhibitors and calcium antagonists, none received drugs known to
interfere with the immunoresponse at the time of the study.
Patients on HD received a normocaloric diet and were placed on
a low water and potassium intake. Patients were dialyzed with
standard capillary artifical kidneys. Low flux dialyzers made from
cuprophane (alpha-600; Gambro, Hechingen, Germany; N = 7)
or hemophane (GFS-16; Gambro; N = 6) as well as polysulfone
(HF-60, Fresenius, Bad Homburg, Germany; N = 8) or polyamide
(GFS-16; Gambro; N = 4) high flux dialyzers were used. Blood
flow was between 150 to 220 mi/mm. Water produced by reverse
osmosis and concentrate were distributed by distinct loops. The
dialysate routinely used contained bicarbonate (34 mmol/liter)
and acetate (3 mmol/liter).
For determination of soluble leukocyte antigens in addition
frozen serum specimens of 12 patients undergoing long-term
hemodialysis were analyzed. These specimens were stored at
—22°C for one to six months until used. Twenty-one non-dialyzed
patients with chronic renal failure (creatinine 3 to 10 mg/dl) were
also tested. The underlying diseases (chronic glomerulonephritis,
interstitial nephropathy, polycystic kidney disease, diabetic ne-
phropathy or unknown etiology) of all patients contributing to the
present study were documented. Twenty-seven healthy subjects
from our clinical staff were recruited as normal controls.
Collection of blood samples
Blood samples were collected from the arterial site of the
arteriovenous fistula at the beginning of HD and from the arterial
blood line after HD. For the determination of soluble leukocyte
antigens blood was drawn into Serum-Monovetten (Sarstedt,
Nümbrecht, Germany). Tubes were allowed to stand for 30
minutes for clotting and were then centrifuged at 1800 g. Sera
were aliquoted and stored at —22°C for further use. For immu-
nophenotyping of peripheral blood monocytes blood was drawn
into tubes containing EDTA as an anticoagulants (EDTA-
Monovetten, Sarstedt, Germany) and directed to flow cytometric
analysis within 30 minutes after venipuncture as described below.
Flow cytometric analysis of membrane-bound CD14
All samples were analyzed on a FACScan flow cytometer
(Becton Dickinson, Heidelberg, Germany). One hundred micro-
liters of blood were incubated with 20 .tl of isothiocyanate-
conjugated (FITC) anti-CD 14 (Leu-M3, Becton Dickinson), and
in a second tube with 20 iil of a FITC-labeled isotype control
(IgG2). After incubation for 15 minutes in the dark and lysis of
erythrocytes, labeled cells were washed with phosphate buffered
saline (PBS) and fixed in 500 d of 2% paraformaldehyde. The
fixed cells were analyzed within 12 hours on the FACScan using
the software Lysis II distributed by Becton Dickinson. Monocytes
were first gated by their light scatter profile in a forward and
sideward scatter plot. The mean FITC-channel fluorescence in-
Fig. 1. Immunofluorescence flow cytomet,y analysis of CDI4 plasma mem-
brane expression on peripheral blood monocytes from HD patients and
nonnal controls. Blood samples were processed and monocytes were gated
by their light scatter properties as defined in the Methods section. Cells
were stained with a FITC-Iabeled mAb against human CD14 or with a
FITC-labeled isotype control niAb. Representative examples for the HD
patient and control group are shown.
tensity of the gated monocytes was measured using four-decade
logarithmic amplification for CD14 and the isotype control stain-
ing. For the determination of specific CD14 expression the
difference in fluorescence intensity between CD14 and control
stains was calculated (Fig. 1). The results were expressed as mean
fluorescence channel (MFC).
Measurement of soluble leukocyte antigens sCD14, sCD8 and
sCD23
For determination of soluble CD14 in serum specimens and cell
culture supernatants, a sandwich ELISA applying two monoclonal
antibodies (IBL, Hamburg, Germany) was used as described
previously [32]. Serum levels of soluble sCD8 and soluble sCD23
were assessed using two sandwich ELISAs (CellFree CD8, T Cell
Science, Cambridge, MA, USA, and sCD23 EIA Kit, The Binding
Site, Heidelberg, Germany). The assays were performed accord-
ing to the manufacturer's specifications.
Measurement of other serum proteins and determination of
hemoconcentration
To determine the effect of dialysis using high-flux membranes
on serum concentrations of soluble CD14, 32-microglobulin (11.8
CD14
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kD) and hemopexin (53 kD) were assessed before and after a
dialysis session.
Serum i32-microglobulin was determind using a solid-phase
time-resolved fluoroimmunoassay (Delfia p2-micro kit, Pharma-
cia-Wallac, Freiburg, Germany). Hemopexin was measured with a
Behring automated nephelometric analyzer (Behringwerke, Mar-
burg, Germany).
The shifts on hemoconcentration during hemodialysis were
evaluated by measuring the hematocrit in EDTA-blood with an
automated cell counter (Coulter counter, Coulter Electronics
Inc., Hialeah, FL, USA) before and after the dialysis session.
Values of serum protein determinations after HD were then
corrected for changes in hemoconcentration.
Determination of the influence of LPS on CDI4 expression in
whole blood samples
LPS (E. coli serotype 055:B5, Sigma, München, Germany) was
resuspended and further diluted in PBS. Whole blood from nine
healthy donors (white blood cell count: 5700 to 8000, mean 6540,
leukocytes/jxl; 307 to 442, mean 364, monocytes/xl) was collected
in EDTA-tubes and directly used for the experiment. One milli-
liter of whole blood was supplemented with 20 pd PBS or 20 jxl of
a LPS solution to give a final LPS concentration of 0.01 ng/ml or
1 ng/ml. Tubes were mounted on a laboratory shaker and incu-
bated at room temperature under gentle rotation. Directly and
after 15, 30, 60, 120 and 240 minutes 100 xl aliquots were
collected and directed to flow cytometric analysis as described
above.
Preparation of peripheral blood monocytes
Whole blood from normal healthy donors collected in EDTA-
tubes was mixed in a ratio 10:1 with a solution of 6% Dextran
T500 (Pharmacia, Freiburg, Germany) suspended in PBS and
incubated for 40 minutes at room temperature. Then the leuko-
cyte-rich plasma was removed and carefully layered on top of a
high osmolarity gradient medium (NycoPrep 1.068; Nycomed,
Norway). After centrifugation for 15 minutes at 600 g the
monocyte ring was collected and the pooled monocyte fractions
were then washed twice with ice-cold PBS. The purity of CD14
cells was evaluated by flow cytometry analysis using the FITC-
labeled anti-CD14 antibody as described above. Absolute num-
bers of cells were counted in a Neubauer microchamber. On
average 57% (49 to 66%) of the isolated cells were CD14
monocytes.
Release of soluble CD14 by cultured monocytes
Isolated peripheral blood monocytes were cultured at a density
of 2 X i0 cells/mi in RPM! 1640 medium supplemented with
10% fetal calf serum (Gibco, Life Technologies, Germany) and
200 mrvi glutamine without any antibiotics. Cultures were per-
formed in 48-well plates (Falcon, Heidelberg, Germany) with 0.5
ml cell suspension per well. For testing the stimulating effect of
LPS on sCD14 release, cells were cultured in the presence of 1
ng/ml or 0.01 ng/ml LPS (E. coli 055:B5). Culture supernatants
were collected and stored at —22°C until measurement of sCD14.
Statistical analysis
Statistical analyses were performed with the software "BIAS"
version 4.0, established by Dr. Hans Ackermann, Department of
i— P= 0.003—iII
Controls CRF HD-CU/HE HD-PS/PA
Fig. 2. CDI4 expression on peripheral blood monocytes in normal controls,
non-dialyzed patients with chronic renal failure (CRF) and hemodialysis
patients (HD) using cuprophane/hemophane (CU/HE) low-flux or polysul-
fone/polyamide (PS/PA) high-flux membranes. Values of specific CD14
fluorescence intensity were expressed as mean fluorescence channel
(MFC). Statistical analysis was performed according to the Mann-Whitney
U test.
Biomathematics, University of Frankfurt/Main, Germany. Differ-
ences in parameters between two groups were elvaluated with the
Mann-Whitney U-Test. Two-tailed Student's i-test was used to
compare differences in parameters before and after hemodialysis.
P values less than 0.05 were considered significant.
Results
Monocyte membrane CD14 expression in non-dialyzed and
dialyzed subjects
Baseline CD14 expression of peripheral blood monocytes from
normal controls or stable hemodialysis patients without infections
was relatively constant. In a longitudinal study the CDI4 expres-
sion for two HD patients and two normal controls was tested
weekly for five weeks, and the variations (mean deviation from the
mean value) were 4.5%, 2%, 3.5%, and 6.9%, respectively.
However, monocytic CD14 expression markedly increased in early
stages of infections, even before onset of clinical symptoms
(Nockher, unpublished results). Those patients and controls with
beginning infectious diseases were excluded retrospectivly from
the study.
CD14 expression was significantly lower in patients undergoing
long-term hemodialysis compared to uremic patients and normal
controls (mean CD14 fluorescence intensity MFC: 500 53 vs.
657 138, P < 0.0001 and 654 113, P < 0.0001). Furthermore,
CD14 expression is also influenced by the type of dialysis mem-
brane used (Fig. 2). Baseline CD14 expression was more de-
creased in patients using polysulfone or polyamide high-flux
membranes than in patients with cuprophane or hemophane
low-flux dialyzers (MFC 469 45 vs. 529 42, P = 0.003). In
uremic patients without HD treatment cell surface CDI4 did not
differ from healthy controls.
Effect of hemodialysis on CD14 expression
Determination of monocyte CD14 expression before and after
a four-hour hemodialysis session revealed a noticeable increase in
the cell surface CD14 (Fig. 3). Mean CDI4 expression was on
average 22% (range 1 to 53%) higher after hemodialysis, with no
significant difference between the various membranes types used.
However, in patients using polysulfone/polyamide membranes,
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Fig. 4. Monocyte CDI4 modulation during hemodialyis. Whole blood was
obtained from two patients at indicated time points and directed to flow
cytometry. A cuprophane (S) and a polysulfone (U) dialyzer were used.
Values were analyzed as mean fluorescence channel of monocyte cell
surface CD14.
pared for two patients in four consecutive dialysis sessions. In one
patient the mCD14 increase varied between 14 and 32%. How-
ever, in the second patient a relativly constant rise of 19, 24, 28
and 24% was observed. We also analyzed the profile of intradia-
lytic changes in CD14 expression during HD in two stable
patients. In both cases cell surface CD14 was increased 15 minutes
after start of the dialysis session and a further continous rise
during HD was observed (Fig. 4).
Serum concentrations of sCDJ4 compared with sCD8 and sCD23
in non-dialyzed and dialyzed subjects
In patients with chronic renal failure without hemodialysis
treatment, serum concentrations of the soluble CD14 antigen
were augmented relative to the values in healthy individuals.
However, the mean sCD14 level in serum specimens from stable
long-term hemodialyzed patients was significantly higher com-
pared to non-dialyzed patients with chronic renal failure, and
about 2.5-fold higher compared to normal controls (Table 1). No
difference in serum sCD14 was found between patients using
high-flux or low-flux dialyzers. In HD patients with acute or
chronic infections a further rise in sCD14 levels (up to 10
mg/liter), and a positive correlation with the acute phase protein
CRP emerged. In addition, the soluble T cell antigen sCD8 was
elevated in HD-patients regardless of the membrane type (P <
0.0001). However, serum values were only 1.5-fold higher com-
pared to healthy subjects. In contrast, the serum concentrations of
the low molecular weight sCD23 antigen were depended on the
type of the dialysis membrane used. Patients treated with high-flux
membranes disclosed about 12-fold elevated sCD23 serum con-
centrations compared to normal controls, and a further increase
was observed by patients using low-flux membranes (Table 1).
Influence of hemodialysis on sCD14 levels
The influence of the dialysis procedure on sCD14 serum levels
was studied in HD patients treated with polysulfone high-flux
membranes. In parallel, levels of p2-microglobulin and hemopexin
were measured, monitoring changes in serum protein concentra-
tions during HD. The low molecular weight 32-microglobulin
Pre-HD Post-HD
Fig. 3. Comparison of CD14 expression on monocytes from long-term
hemodialysis patients undeioing HD with cuprophane/hemophane (A) or
polysulfone/polyamide (B) dialyzers before (Pre-HD) and after (Post-HD) the
dialysis session. Patients were dialyzed for four hours as described in the
Methods section. Results are expressed as mean fluorescence channel of
specific CD14 expression.
CD14 increase was slightly higher compared to those on cu-
prophane/hemophane membranes (median increase 26.8% vs.
19.9%). Intraindividual changes of CD14 expression were corn-
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Table 1. Serum concentrations of soluble leukocyte antigens
N
CD14
pg/mi
sCD8
U/mi
sCD23
ng/mi
Controls 2.2 0.47 343 59 1.3 1.0
27
CRF 3.9 1.0 ND ND
21 P <o.000la
HD-LF 5.5 1.4 524 153 24.6 14.7
22 P < 0.0001
p <
P < 0.0001 P < o.000la
HD-HF 5.2 1.2 550 143 15.0 8.8
15 P < o.ooola
p <
i < o.000ia p < o.ooor'
p < o.o5
Soluble leukocyte antigens were determined in serum from healthy
controls, non-dialyzed patients with chronic renal failure (CRF) and
hemodialysis patients treated with low-flux (HD-LF) or high-flux (HD-
HF) membranes. Results are expressed as mean sii Statistical compar-
isons between the patients groups have been obtained using the Mann-
Whitney U test.
a versus controls
versus CRF
HD-HF versus HD-LF
ND is not determined.
(11.8 kD), heavily accumulated in long-term hemodialyzed pa-
tients, is known to be eliminated by high-flux membranes. He-
mopexin, a liver-derived 53 kD protein with the identical molec-
ular weight of sCDI4, was used as additional marker since
normally hepatic protein synthesis is not influenced by HD. The
results are summarized in Table 2.
As expected, f32-microglobulin levels markedly dropped during
HD due to filtration through HF-membranes. Serum levels of
hemopexin did not change, indicating no loss of this 53 kD protein
during hemodialysis. However, determination of soluble CDI4
revealed a slight but statistically significant increase in sCD14
serum concentrations after the dialysis session.
Taken together, these clinical studies clearly demonstrate the
up-regulation of CD14 expression by peripheral blood monocytes
during hemodialysis. Also, levels of the soluble CD14 antigen
were more elevated in HD patients relative to CRF patients
without HD treatment, indicating an enhanced release of the
CD14 antigen during HD demonstrated by increased serum levels
after hemodialysis.
Influence of LPS on CD14 expression in whole blood samples
To establish the influence of endotoxin on monocyte CDI4
expression in whole blood, we assessed in in vitro experiments the
changes of cell surface CD14 in response to LPS over a four-hour
incubation period.
The expression of CD14 on monocytes was found to slowly
increase after blood collection, while addition of LPS led to a
pronounced stimulation of CD14 expression (Table 3). A strong
increase in CDI4 expression was already found after 30 minutes
of incubation by challenge with I nglml LPS. After 60 minutes,
0.01 nglml LPS also significantly increased cell surface CDI4 as
compared to the controls.
The mean CD14 increase per minute ( MFC/min) was maxi-
mal in the first 30 minutes by addition of 1 nglml LPS (9.6
MCF/min) and between 30 and 60 minutes for 0.01 ng/ml LPS (6.2
MFC/min) followed by a continous decline. After 120 minutes the
up-regulation of membrane-bound CDI4 was nearly completed.
Table 2. Influence of high-flux dialysis on levels of sCDI4 compared
with other serum proteins
Pre-HD Post-HD
Pre versus post
P value
132-microglobulin 30.2 6.3 13.9 5.0 <0.0001
Hemopexin 778 117 776 128 ns
sCD14 5.1 1.0 6.1 1.2 <0.001
Data are mean SD of serum protein levels during dialysis session
(mg/liter).
Serum protein levels were determined from 12 patients treated with
high-flux polysulfone membranes for 4 hours. Values after hemodialysis
were corrected for hemoconcentration. Two-tailed Student's t-test was
used for statistical analysis. NS is not significant.
Effect of LPS on sCD14 release of cultured peripheral blood
monocytes
The effect of lipopolysaccharide on the release of the sCDI4
antigen by human monocytes was determind by incubating puri-
fied monocytes in the presence or absence of LPS for five days,
and measuring sCDI4 in culture supernatants. The results are
shown in Figure 5. Soluble CD14 concentrations in supernatants
of untreated monocytes subsequently increased during culture.
Addition of 0.01 or 1 nglml LPS significantly enhanced sCD14
concentrations after one day and maintained elevated release of
the sCD14 antigen during the following four days.
Discussion
With their multiple immunobiological activities monocytes!
macrophages play a central role in regulating the immune re-
sponse. In the last decade a number of investigations reported
disturbances in monocyte function on hemodialysis. However,
whereas most studies have looked at various aspects of cytokine
secretion, information about the expression of cell surface anti-
gens with respect to monocyte activation is limited. In this report,
we describe the up-regulation of the cell surface expression of the
monocyte CD14 antigen after a dialysis session together with a
reduced baseline CD14 expression and elevated serum levels of
the soluble CDI4 antigen.
The changes of membrane antigen expression such as CD14,
HLA-DR [13] and complement receptors [37] by peripheral blood
moriocytes reflect a state of activation induced by the hemodialysis
procedure. In vivo stimulation of monocytes during HD was also
described by other investigators. Spontaneous production of
TNF-a by cultured peripheral blood monocytes obtained from
HD patients was enhanced as compared to monocytes from
controls [38]. Furthermore, after HD an increased spontaneous
IL-I [10] or TNF-a [11, 38] secretion compared to the predialysis
state has been reported. These in vitro data are supported by in
vivo results, where increased serum levels of IL-1f3 [39] or TNF-cw
were observed 60 minutes after start of the dialysis session [11].
Several mechanisms of monocyte activation during hemodialy-
sis have been proposed. The direct interaction with the artifical
surface of the dialyzer membrane has been favored as the primary
mechanism [40]. In addition, exposure to bacterial endotoxin
through transmembrane passage of LPS is thought to be an
important factor in the monocyte activation process [20, 22, 41].
Recent work from different laboratories showed that the CD14
antigen mediates monocyte recognition of lipopolysaccharide [25,
30, 31, 42]. In our in vitro studies LPS concentrations as low as
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Table 3. Effect of lipopolysaccharide on monocyte CD14 expression in whole blood
.LPS concentration:
nglml
Incubation time
0
0 mm
0.01 1 0
30 mm
0.01 1
60 mm 120 mm 240 mm
0 0.01 1 0 0.01 1 0 0.01 1
CD14 MFC
Mean
SD
648 649 668 690 794 956C 758 980 1298' 884 ll94' 1354C 940 1279b 1412'
Whole blood specimens from nine healthy donors were incubated for 4 hours with 0.01, 1 ng/ml or without LPS at room temperature, and monocyte
CD14 expression was evaluated directly and after 15, 30, 60, 120 and 240 mm. Values of specific CD14 fluorescence intensity (MCF) are expressed as
the mean and so from the nine single experiments. Statistical comparisons of CD14 expression in the presence of LPS versus incubation without LPS
were carried out at selected timepoints using the Mann-Whitney U test.
a P < 0.05
h P < 0.01
P < 0.001
1 2 3 4
Incubation time, days
Fig. 5. Lipopolysaccharide-induced sCD14 release by cultured blood mono-
cytes. Two X iO monocytes/mi were cultured for five days in RPMI 1640
medium with 10% FCS either without (LIi) or in the presence of 0.01 ng/ml
(ti) or I ng/ml () LPS. Soluble CD14 antigen was determind in culture
supernatants by a sandwich ELISA. Each column represents the mean and
SD of 5 experiments. *Significant increase (P < 0.001) compared with the
culture without LPS.
0.01 ng/ml induced up-regulation of CD14 expression. Such trace
amounts of LPS may always be present in the dialysate compart-
ment as well as in the dialysis equipment. Thus, the observed
augmentation of cell surface CD14 after a dialysis session may
reflect exposure of circulating monocytes to endotoxin present in
the extracorporeal blood circuit. In contrast, patients undergoing
peritoneal dialysis exhibit normal membrane CD14 (unpublished
data). The chronic stimulation of CD14 expression through
repeated exposure to LPS during each dialysis session is thought
to lead to the decreased baseline CD14 expression observed in
long-term hemodialyzed patients as compared to uremic patients
without HD treatment. Kinetic studies demonstrated a rise in
CD14 expression as early as 15 to 30 minutes after start of the
dialysis, coincident with the LPS-induced activation of CD14
expression in vitro. In humans, increased plasma concentrations of
TNF-cs are observed 60 minutes after the injection of LPS [43, 44].
Therefore, the elevated TNF-a serum levels 60 minutes after
onset of HD [101 also suggest exposure to LPS during hemodial-
ysis.
At the moment the reason for the further decreased baseline
CD14 expression in patients treated with high-flux polysulfone or
polyamide devices remains unclear. Polyamide membranes were
reported to have a lower transmembrane passage of LPS due to
LPS absorption through hydrophobic interactions [45, 46]. On the
other hand, the contact with the different chemical composition of
the membrane surface material could also influence CD14 expres-
sion. However, further studies are necessary to investigate the
direct influence of the membrane materials on cell surface CD14.
Consistent with earlier reports from our laboratory, the release
of soluble CD14 was increased from cultured peripheral blood
monocytes treated with lipopolysaccharide. Only trace amounts of
LPS were necessary to increase sCD14 release (10 pg/ml) or IL-13
secretion (0.1 pg/mI, unpublished data). The enhanced sCD14
5 release is thought to be a result of the increased cell surface
CD14, since shedding of the membrane antigen is reported to be
a mechanism of down-modulation on stimulated monocytes [47].
Thus, the elevated sCD14 serum concentrations in HD patients
apparently reflect not only the renal impairment but also a
repeated stimulation of CD14 expression with subsequent release
of sCD14 during each dialysis session, as could be demonstrated
by the increased serum levels after HD. This explains why the
increments in serum concentrations of the 53 kD sCD14 [48] and
the 54 kD sCD8 [49] molecules, both normally filtered by the
glomerulus at minimal rates, differ in HD patients compared to
healthy subjects. The significantly elevated sCD14 in HD patients
relative to non-dialyzed patients with CRF gives further impact
for the influence of HD-treatment on sCD14 release. The 20 kD
sCD23 antigen [50] is even more accumulated in HD patients
compared to healthy controls, due to loss of renal filtration and
shedding of the CD23 antigen during HD, the latter resulting in a
marked rise in sCD23 serum levels after HD [51].
The physiological importance of elevated sCD14 serum levels
in hemodialysis is not yet clear. HD-patients with chronic HCV
infection or acute bacterial infections have significant increased
sCD14 values compared to stable HD patients [52]. In any case,
sCD14 participates as an accessory molecule in LPS-induced
changes in various cell functions [36, 53, 54]. Therefore, elevated
sCD14 serum levels may enhance cellular effects mediated by LPS
and/or LBP-CD14 complexes. In addition, the reduced basal
CD14 expression in HD patients may account for a decreased
stimulatory capacity of monocytes by endotoxins, resulting in an
impaired immunoresponse to bacterial infections.
In conclusion, our results presented herein show that long-term
hemodialysis leads to an ongoing stimulation of monocyte CD14
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expression which may result in the decreased baseline CD14
expression and elevated sCD14 serum levels. However, whether
changes in CD14 expression and sCD14 release contribute to a
disturbed immune response to infections in HD patients will
require further investigation. Also, the prevention of chronic
exposure to even trace amounts of endotoxin during hemodialysis
remains a challenge for the future.
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